KIT 2014
Alternative Names: KIT-2014Latest Information Update: 25 Jun 2026
At a glance
- Originator Kither Biotech
- Class Antifibrotics; Peptides
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Yes - Cystic fibrosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cystic fibrosis
- Preclinical Bronchiectasis; Respiration disorders
Most Recent Events
- 19 Jun 2026 Pharmacokinetics and adverse event data from a phase I trial in Cystic fibrosis released by Kither Biotech
- 08 Jun 2026 Preclinical for Respiration disorders in Italy (Inhalation) (Kither Biotech Pipeline, June 2026)
- 28 Apr 2026 No recent reports of development identified for research development in Respiration-disorders in Italy (Inhalation)